Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.40 |
| ▸ | PGR | P06401 | 3/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 9/20 | 0.39 |
| ▸ | CNR1 | P21554 | 8/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707261 | 0.84 | CNR2 (0.43) | CNR2CNR1OPRM1CCR5 | |
| SCHEMBL921816 | 0.77 | CNR1 (0.48) | CNR2CNR1 | |
| SCHEMBL707467 | 0.76 | PLD1 (0.41) | CNR2CNR1 | |
| SCHEMBL707084 | 0.76 | DRD2 (0.42) | CNR2CNR1OPRM1CCR5 | |
| SCHEMBL1306000 | 0.75 | OPRM1 (0.61) | OPRM1 | |
| SCHEMBL2798206 | 0.74 | HTR3E (0.45) | OPRM1 | |
| SCHEMBL17095965 | 0.71 | OPRM1 (0.39) | OPRM1CCR5 | |
| SCHEMBL3839394 | 0.71 | TP53 (0.37) | OPRM1CCR5 | |
| SCHEMBL1062230 | 0.71 | OPRM1 (0.56) | OPRM1 | |
| SCHEMBL9986091 | 0.71 | KCNH2 (0.39) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | NR3C1 4806/4885PGR 4681/4885NR3C2 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.